|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Shire Pharmaceuticals Group plc, a British biotech company. |
|---|---|
| Transferring Party | Transkaryotic Therapies, Inc., a US-based biopharmaceutical developer of therapeutics primarily for the treatment of rare genetic diseases caused by protein deficiencies. |
| Sector | Biopharmaceuticals |
| Date | April 22, 2005 |
| Analysis Transkaryotic will help Shire gain access to an area of specialty pharmaceuticals with few competitors. Builds on Shire's European and US specialty sales and marketing capabilities; leverages Shire's experience in renal and hematology. Deal value about $1.6 billion. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |